EMA Mulls Dropping Comparative Efficacy Trials For Biosimilars
European Agency Kicks Off Consultation On Whether Such Studies Are Always Necessary
In a move that could hold major promise for the biosimilars industry, the European Medicines Agency has opened up a consultation on re-evaluating the need for comparative efficacy studies to support biosimilar applications.
